Kodiak Sciences Inc Common Stock (KOD) Stock Price

KODStock
$39.46+264.90%52W
Market Cap$2.48B
P/E
PEG Ratio
Div yield
Beta2.22

KOD Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)40.18%
Price vs S&P 500 (4W)-10.67%
VGM Score62.36

KOD Earnings Surprise History

Q2 25-1.03est. -1.05
Q3 25-1.16est. -1.04
Q4 25-1.04est. -1.05
Q1 26-0.94est. -1.01
Q2 26-1.05est. -0.96

KOD Analyst Recommendations

May 2026
Jun 2026
Jul 2026
Aug 2026
4.00
4.09
4.09
4.10

Industry Peers — Biological Products(183)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
KODKodiak Sciences Inc Common Stock
B$39.46
AMGNAmgen IncCCB$442.24
GILDGilead Sciences IncCBB$148.77
MRNAModerna, Inc. Common StockDCA$158.83
ARGXargenx SE American Depositary SharesDAB$1019.49
RVMDRevolution Medicines, Inc. Common StockFA$211.38
BIIBBiogen Inc. Common StockCDB$220.77
BNTXBioNTech SE American Depositary ShareCCB$114.05
NBIXNeurocrine Biosciences IncCBC$153.37
EXELExelixis IncCBB$56.72
HALOHalozyme Therapeutics, Inc.CBA$109.32

About Kodiak Sciences Inc Common Stock

Kodiak Sciences is a biopharmaceutical company developing novel therapeutics for high-prevalence retinal diseases, with a focus on wet age-related macular degeneration. The company's clinical-stage pipeline includes an antibody biopolymer conjugate for previously untreated wet AMD patients, along with additional candidates such as Tarcocimab tedromer, KSI-501, and KSI-101. These programs target significant unmet needs in retinal disease treatment.